Evidence map›Paper›PMID 31969339›Full record

ArticleClinical cancer research : an official journal of the American Association for Cancer Research2020

A Chimeric Signal Peptide-Galectin-3 Conjugate Induces Glycosylation-Dependent Cancer Cell-Specific Apoptosis.

Sok-Hyong Lee, Fatima Khwaja Rehman, Kari C Tyler, Bing Yu, Zhaobin Zhang, Satoru Osuka, Abdessamad Zerrouqi, Milota Kaluzova, Costas G Hadjipanayis, Richard D Cummings and 3 more

Open access · greenAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Clinical cancer research : an official journal of the American Association for Cancer Research, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
0.6field-weighted citation impact, top 36% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 10 citations in OpenAlex.

  1. Review
  2. Review
  3. Article
  4. Review
  5. Review
  6. Article
  7. Review
  8. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 1 institution in 1 country.

Sok-Hyong LeeDepartment of Neurosurgery, Emory University, Atlanta, Georgia.
Fatima Khwaja RehmanDepartment of Neurosurgery, Emory University, Atlanta, Georgia.ORCID 0000-0001-7941-4107
Kari C TylerDepartment of Neurosurgery, Emory University, Atlanta, Georgia.
Bing YuDepartment of Neurosurgery, Emory University, Atlanta, Georgia.ORCID 0000-0002-7259-8190
Zhaobin ZhangDepartment of Neurosurgery, Emory University, Atlanta, Georgia.
Satoru OsukaDepartment of Neurosurgery, Emory University, Atlanta, Georgia.
Abdessamad ZerrouqiDepartment of Neurosurgery, Emory University, Atlanta, Georgia.ORCID 0000-0002-2628-473X
Milota KaluzovaDepartment of Neurosurgery, Emory University, Atlanta, Georgia.
Costas G HadjipanayisDepartment of Neurosurgery, Emory University, Atlanta, Georgia.ORCID 0000-0001-8615-6644
Richard D CummingsWinship Cancer Institute, Emory University, Atlanta, Georgia.
Jeffrey J OlsonDepartment of Neurosurgery, Emory University, Atlanta, Georgia.
Narra S DeviDepartment of Neurosurgery, Emory University, Atlanta, Georgia.
Erwin G Van MeirDepartment of Neurosurgery, Emory University, Atlanta, Georgia. evanmeir@uab.edu.ORCID 0000-0003-2444-7707
Emory University · US

Funding

THERAPEUTIC MODULATION OF ANGIOGENESIS IN HUMAN GLIOMASR01CA086335 · NCI · EMORY UNIVERSITY · PI VAN MEIR, ERWIN G. · 2000 to 2011
$3.9M
Evaluating ADGRB3 as a tumor suppressor epigenetically silenced in WNT medulloblastomaR01CA235162 · NCI · UNIVERSITY OF ALABAMA AT BIRMINGHAM · PI VAN MEIR, ERWIN G. · 2019 to 2024
$2.3M
THE TUMOR ANTIGENS TN AND SIALYLTN IN HUMAN COLORECTAL CARCINOMAU01CA168930 · NCI · EMORY UNIVERSITY · PI CUMMINGS, RICHARD D, SMITH, DAVID FLETCHER · 2012 to 2016
$2.0M
Targeting Mechanisms of Medulloblastoma FormationR01NS096236 · NINDS · UNIVERSITY OF ALABAMA AT BIRMINGHAM · PI VAN MEIR, ERWIN G. · 2016 to 2020
$1.9M
Defining mechanisms of extracellular communication for cancer therapyR01CA163722 · NCI · EMORY UNIVERSITY · PI VAN MEIR, ERWIN G. · 2013 to 2017
$1.7M
NCI NIH HHS R01 CA086335NCI NIH HHS R01 CA163722NCI NIH HHS R01 CA235162NCI NIH HHS U01 CA168930NINDS NIH HHS R01 NS096236
6 · The paper itself

Abstract

purposeExploitation of altered glycosylation in cancer is a major goal for the design of new cancer therapy. Here, we designed a novel secreted chimeric signal peptide-Galectin-3 conjugate (sGal-3) and investigated its ability to induce cancer-specific cell death by targeting aberrantly EXPERIMENTAL

designsGal-3 was genetically engineered from Gal-3 by extending its N-terminus with a noncleavable signal peptide from tissue plasminogen activator. sGal-3 killing ability was tested on normal and tumor cells

resultsWe found sGal-3 preferentially binds to β1 integrin on the surface of tumor cells due to aberrant

conclusionsWe demonstrate that sGal-3 kills aberrantly glycosylated tumor cells and antagonizes tumor growth through a novel integrin β1-dependent cell-extrinsic apoptotic pathway. These findings provide proof-of-principle that aberrant

Indexed as

ApoptosisProtein Sorting SignalsAnimalsBlood ProteinsCell ProliferationFemaleGalectinsGliomaGlycosylationHumansIntegrin beta1MiceMice, NudePeptide FragmentsSignal TransductionTumor Cells, CulturedBlood ProteinsGalectinsIntegrin beta1LGALS3 protein, humanPeptide FragmentsProtein Sorting Signals

Identifiers

PMID31969339
PMCPMC7580863
OpenAlexW3001819867

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.